Volume 28, Issue 1

January 2010

Filter by

Volume:

Sort by

Date published:

New to old Old to new

7 articles in this issue

Should Financial Incentives be Used to Differentially Reward ‘Me-Too’ and Innovative Drugs?
Brita Pekarsky
Current Opinion 23 September 2012 Pages: 1 - 17
Adverse Drug Interactions
Ryan Mayhew
June M. McKoy
Charles L. Bennett
Commentary 23 September 2012 Pages: 19 - 22
The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
Fred J. Hellinger
William E. Encinosa
Original Research Article 23 September 2012 Pages: 23 - 34
Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma
Eric Deconinck
Houda Miadi-Fargier
Pauline Brice
Original Research Article 23 September 2012 Pages: 35 - 46
Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
Virginia M. Rosen
Douglas C. A. Taylor
Milton C. Weinstein
Original Research Article 23 September 2012 Pages: 47 - 60
A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
Lisa M. Meckley
James M. Gudgeon
David L. Veenstra
Original Research Article 23 September 2012 Pages: 61 - 74
Erlotinib
Katherine A. Lyseng-Williamson
Adis Pharmacoeconomic Drug Evaluation 23 September 2012 Pages: 75 - 92

Search